Abstract
Cell-based therapies have emerged as a promising frontier in regenerative medicine, offering potential treatments for various degenerative, autoimmune, and genetic disorders. However, their clinical translation is accompanied by complex ethical and regulatory challenges that must be addressed to ensure patient safety, equitable access, and scientific integrity. This review explores the intricate landscape of global regulatory frameworks governing cell-based therapies, highlighting key obstacles such as inconsistent international guidelines, prolonged approval timelines, and ethical considerations. The lack of regulatory harmonization often impedes innovation and delays the availability of advanced treatments to patients in need. In addition, stringent requirements can pose barriers for emerging biotech start-ups, limiting competition and technological advancements. Despite these challenges, regulatory frameworks also present opportunities to foster innovation, enhance patient safety, and streamline drug approval process. Collaborative efforts between policymakers, regulatory bodies, industry leaders, and research institutions are crucial to developing standardized yet adaptable guidelines that accommodate scientific progress while maintaining stringent safety protocols. By fostering a regulatory ecosystem that encourages innovation without compromising safety, stakeholders can unlock the potential of cell-based therapies, paving the way for their widespread adoption and integration into clinical practice.